OBJECTIVE: To explore the correlation of chemotherapy efficacy in malignant lymphomas with the expression level of multidrug resistance gene 1 (mdr1) mRNA, multidrug resistance-associated protein (MRP), and P-glycoprotein (P-gp). METHODS: Using the methods of semi quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and flow cytometry (FCM), a prospective research was performed to detect the expression levels of molrl gene, MRP gene, and p-gp in the lymph nodes of 23 untreated first visit (HD1, NHL 22) and 23 recurrent (HD 5, NHL 18) lymphoma patients. Eight normal human lymph nooles were used as controls. RESULTS: The expression levels and positive rates of mdr1 and P-gp in recurrent patients were higher than those in untreated patients (P < 0.001). There was no difference in MRP gene expression level and positive rate between recurrent and untreated patients (P > 0.05). The chemotherapy effective rates were lower in mdr1 gene and P-gp positive expression patients (33.33% and 26.67%) than in negative expression patients (85.71% and 83.87%) (P < 0.001). Relevant analysis showed that there was a significant relevance in expression level between mdr1 gene and P-gp (r = 0.296 3, P < 0.05), but there was no correlation between mdr1 and MRP or between MRP and P-gp (r = 0.072 3, P > 0.05; r = 0.081 8, P > 0.05). CONCLUSION: mdr1 gene and P-gp expression levels are dominant mechanisms of clinical drug resistance of lymphomas, whereas, MRP gene appears to play no role in that course. mdr1 gene and P-gp expression levels are relevant to chemotherapy efficacy, however, MRP gene expression level seems to have no impact on it.
OBJECTIVE: To explore the correlation of chemotherapy efficacy in malignant lymphomas with the expression level of multidrug resistance gene 1 (mdr1) mRNA, multidrug resistance-associated protein (MRP), and P-glycoprotein (P-gp). METHODS: Using the methods of semi quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and flow cytometry (FCM), a prospective research was performed to detect the expression levels of molrl gene, MRP gene, and p-gp in the lymph nodes of 23 untreated first visit (HD1, NHL 22) and 23 recurrent (HD 5, NHL 18) lymphomapatients. Eight normal human lymph nooles were used as controls. RESULTS: The expression levels and positive rates of mdr1 and P-gp in recurrent patients were higher than those in untreated patients (P < 0.001). There was no difference in MRP gene expression level and positive rate between recurrent and untreated patients (P > 0.05). The chemotherapy effective rates were lower in mdr1 gene and P-gp positive expression patients (33.33% and 26.67%) than in negative expression patients (85.71% and 83.87%) (P < 0.001). Relevant analysis showed that there was a significant relevance in expression level between mdr1 gene and P-gp (r = 0.296 3, P < 0.05), but there was no correlation between mdr1 and MRP or between MRP and P-gp (r = 0.072 3, P > 0.05; r = 0.081 8, P > 0.05). CONCLUSION:mdr1 gene and P-gp expression levels are dominant mechanisms of clinical drug resistance of lymphomas, whereas, MRP gene appears to play no role in that course. mdr1 gene and P-gp expression levels are relevant to chemotherapy efficacy, however, MRP gene expression level seems to have no impact on it.